Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

2024.03.08
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).
Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

2024.03.06
Lymphoma is one of the fastest-growing malignant tumors worldwide, and the incidence rate in China has been gradually increasing in recent years, posing a serious threat to the health of the population. From January 26 to 28, 2024, the "Work Conference of the Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee of the Chinese Society of Clinical Oncology (CSCO) and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma Diseases" was successfully held in Haikou. Professor Huilai Zhang from Tianjin Medical University Cancer Institute and Hospital shared insights at the conference on the survival status and diagnosis and treatment strategies for patients with indolent lymphoma, frontline treatment strategies for mantle cell lymphoma, and research progress on immunosuppressants. Following the conference, Oncology Frontier - Hematology Frontier invited Professor Zhang for an in-depth sharing session.
2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL

2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL

2024.03.04
The Fourth China Hematology Development Conference was held in Tianjin from January 5 to 7, 2024. Themed "Broad Hematology, Public Health, and Overall Well-being," the conference centered around the core development directions of hematology, as well as major disciplinary issues faced in basic hematology research, translation, and clinical diagnosis and treatment in the new era. It featured discussions and in-depth explorations of hot topics and frontiers, aiming to promote the construction and vigorous development of the hematology field. On this occasion, Professor Ying Wang , Director of the Comprehensive Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, was interviewed to share the progress and breakthroughs in immunotherapy within the field of Acute Lymphoblastic Leukemia (ALL).
WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.
WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

2024.01.19
The 2023 World Lung Cancer Congress (WCLC) took place at the Singapore Expo Center from September 9th to 12th. Dr. Shi Meiqi from Jiangsu Cancer Hospital presented crucial findings in a phase 1/2 clinical study at this conference (MA15.09). In an interview with " Oncology Frontier ," Dr. Shi Meiqi shared research insights, key results, and treatment strategies for KRAS mutation non-small cell lung cancer patients.
WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.
Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

2024.01.18
The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of urothelial carcinoma (UC), significant progress has been made in research. Immunotherapy with immune checkpoint inhibitors (ICIs) in the first-line treatment for advanced UC, as reported in the final analysis of the IMvigor130 study, has provided more information on the population benefiting from immune therapy. Additionally, immunotherapy has expanded into early-stage treatment, with the updated 3-year follow-up data from the CheckMate 274 study showing a Disease-Free Survival (DFS) of up to 52.6 months in the PD-L1 > 1% subgroup. Furthermore, different targets such as Trop-2 and Nectin-4 in antibody-drug conjugates (ADCs) are being explored in various treatment modalities and are extending from later-line to first-line treatment.